not vested
Despite all these setbacks, Pinxter Analytics believes that Teva's current valuation is not justified.
The author's investment thesis is based on three main points.
The first is that Teva's sales are still
growing at around 2% on an organic basis. In addition, this does not take into account the fact Teva has
600 generics in the pipeline that could be potentially approved in the next two years, according to the author.
Further, the other notes that these generic launches, combined with a price reduction for Copaxone to compete with Mylan generic, could lead to organic sales growth returning to 4-5%.
The author believes that this will also lead to a higher earnings growth rate.
Finally, Pinxter Analytics adds that with the company continuing to generate high cash flows, making acquisitions in the future and reducing its debt are all factors that could enhance shareholder value.
Source: Seeking Alpha
https://seekingalpha.com/article/412710 ... ngcom_feed
It's all about "how much you made when you were right" & "how little you lost when you were wrong"